Product Pathways - DNA Damage
Phospho-p53 (Ser15) (16G8) Mouse mAb #9286
Applications | Reactivity | Sensitivity | MW (kDa) | Isotype |
---|---|---|---|---|
W IF-IC F | H | Endogenous | 53 | Mouse IgG1 |
Applications Key:
W=Western Blotting
IF-IC=Immunofluorescence (Immunocytochemistry)
F=Flow Cytometry
Reactivity Key:
H=Human
Species cross-reactivity is determined by Western blot.
Protocols
- 9286:
- Flow, Immunofluorescence, Western Blotting
Specificity / Sensitivity
Phospho-p53 (Ser15) (16G8) Mouse mAb detects endogenous levels of p53 only when phosphorylated at serine15. The antibody does not cross-react with p53 phosphorylated at other sites.
Source / Purification
Monoclonal antibody is produced by immunizing mice with a synthetic phospho-peptide (KLH-coupled) corresponding to residues surrounding Ser15 of human p53.
Western Blotting
Western blot analysis of extracts from MvlLu cells, untreated, hydroxyurea-treated (20 mM) or UV-treated, using Phospho-p53 (Ser15) (16G8) Mouse mAb.
Flow Cytometry
Flow cytometric analysis of HT-29 cells, untreated (blue) or UV-treated (green), using Phospho-p53 (Ser15) (16G8) Mouse mAb compared to a nonspecific negative control antibody (red).
IF-IC
Confocal immunofluorescent analysis of HT-29 cells, untreated (left) or UV-treated (right), using Phospho-p53 (Ser15) (16G8) Mouse mAb (green). Actin filaments have been labeled with Alexa Fluor® 555 phalloidin (red).
Background
The p53 tumor suppressor protein plays a major role in cellular response to DNA damage and other genomic aberrations. Activation of p53 can lead to either cell cycle arrest and DNA repair or apoptosis (1). p53 is phosphorylated at multiple sites in vivo and by several different protein kinases in vitro (2,3). DNA damage induces phosphorylation of p53 at Ser15 and Ser20 and leads to a reduced interaction between p53 and its negative regulator, the oncoprotein MDM2 (4). MDM2 inhibits p53 accumulation by targeting it for ubiquitination and proteasomal degradation (6,7). p53 can be phosphorylated by ATM, ATR and DNA-PK at Ser15 and Ser37. Phosphorylation impairs the ability of MDM2 to bind p53, promoting both the accumulation and activation of p53 in response to DNA damage (4,5). Chk2 and Chk1 can phosphorylate p53 at Ser20, enhancing its tetramerization, stability and activity (8,9). p53 is phosphorylated at Ser392 in vivo (11,12) and by CAK in vitro (12). Phosphorylation of p53 at Ser392 is increased in human tumors (14) and has been reported to influence the growth suppressor function, DNA binding and transcriptional activation of p53 (10,11,13). p53 is phosphorylated at Ser6 and Ser9 by CK1δ and CK1ε both in vitro and in vivo (10,15). Phosphorylation of p53 at Ser46 regulates the ability of p53 to induce apoptosis (16). Acetylation of p53 is mediated by p300 and CBP acetyltransferases. Inhibition of deacetylation suppressing MDM2 from recruiting HDAC1 complex by p19 (ARF) stabilizes p53. Acetylation appears to play a positive role in the accumulation of p53 protein in stress response (17). Following DNA damage, human p53 becomes acetylated at Lys382 (Lys379 in mouse) in vivo to enhance p53-DNA binding (18). Deacetylation of p53 occurs through interaction with the SIRT1 protein, a deacetylase that may be involved in cellular aging and the DNA damage response (19).
- Levine, A.J. (1997) Cell 88, 323-331.
- Meek, D.W. (1994) Semin. Cancer Biol. 5, 203-210.
- Milczarek, G.J. et al. (1997) Life Sci. 60, 1-11.
- Shieh, S.Y. et al. (1997) Cell 91, 325-334.
- Tibbetts, R.S. et al. (1999) Genes Dev. 13, 152-157.
- Chehab, N.H. et al. (1999) Proc. Natl. Acad. Sci. USA 96, 13777-13782.
- Honda, R. et al. (1997) FEBS Lett. 420, 25-27.
- Shieh, S.Y. et al. (1999) EMBO J. 18, 1815-1823.
- Hirao, A. et al. (2000) Science 287, 1824-1827.
- Kohn, K.W. (1999) Mol. Biol. Cell 10, 2703-2734.
- Hao, M. et al. (1996) J. Biol. Chem. 271, 29380-29385.
- Lu, H. et al. (1997) Mol. Cell. Biol. 17, 5923-5934.
- Lohrum, M. and Scheidtmann, K.H. (1996) Oncogene 13, 2527-2539.
- Ullrich, S.J. et al. (1993) Proc. Natl. Acad. Sci. USA 90, 5954-5958.
- Knippschild, U. et al. (1997) Oncogene 15, 1727-1736.
- Oda, K. et al. (2000) Cell 102, 849-862.
- Ito, A. et al. (2001) EMBO J. 20, 1331-1340.
- Sakaguchi, K. et al. (1998) Genes Dev. 12, 2831-2841.
- Solomon, J.M. et al. (2006) Mol. Cell. Biol. 26, 28-38.
Application References
- Hammond, E. M. et al. (2002) Hypoxia links ATR and p53 through replication arrest. Mol. Cell. Biol. 22, 1834-1843. This article references the use of Phospho-p53 (Ser15) (16G8) Mouse mAb in the following applications: Western Blotting
- Scott, S. P. et al. (2002) Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer. Proc. Natl. Acad. Sci. USA 99, 925-930. This article references the use of Phospho-p53 (Ser15) (16G8) Mouse mAb in the following applications: Western Blotting
- Shono, T. et al. (2002) Apoptosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation. Cancer Res. 62, 1069-1076. This article references the use of Phospho-p53 (Ser15) (16G8) Mouse mAb in the following applications: Western Blotting
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
Companion Products
- 9281 Phospho-p53 (Ser392) Antibody
- 9282 p53 Antibody
- 9284 Phospho-p53 (Ser15) Antibody
- 9285 Phospho-p53 (Ser6) Antibody
- 9287 Phospho-p53 (Ser20) Antibody
- 9288 Phospho-p53 (Ser9) Antibody
- 9289 Phospho-p53 (Ser37) Antibody
- 9919 Phospho-p53 Antibody Sampler Kit
- 7076 Anti-mouse IgG, HRP-linked Antibody
- 7720 Prestained Protein Marker, Broad Range (Premixed Format)
- 7727 Biotinylated Protein Ladder Detection Pack
- 7003 20X LumiGLO® Reagent and 20X Peroxide
This product is for in vitro research use only and is not intended for use in humans or animals. This product is not intended for use as therapeutic or in diagnostic procedures.